1. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients
- Author
-
Nicolas Chapuis, François Dreyfus, Norbert Ifrah, Valérie Bardet, Catherine Lacombe, Sophie Park, Odile Blanchet, Patrick Mayeux, Pascale Cornillet-Lefebvre, Bruno Lioure, Jerome Tamburini, Caroline Elie, Francis Witz, Didier Bouscary, Valérie Ugo, and Philippe Broët
- Subjects
Male ,medicine.medical_specialty ,Myeloid ,Immunology ,Biochemistry ,Disease-Free Survival ,Leukocyte Count ,Phosphatidylinositol 3-Kinases ,Myelogenous ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Protein kinase B ,Survival rate ,PI3K/AKT/mTOR pathway ,Phosphoinositide 3-kinase ,L-Lactate Dehydrogenase ,biology ,business.industry ,Nuclear Proteins ,Cell Biology ,Hematology ,medicine.disease ,Enzyme Activation ,Survival Rate ,Leukemia, Myeloid, Acute ,Leukemia ,Endocrinology ,medicine.anatomical_structure ,fms-Like Tyrosine Kinase 3 ,Fms-Like Tyrosine Kinase 3 ,ras Proteins ,biology.protein ,Cancer research ,Female ,Blast Crisis ,business ,Nucleophosmin ,Proto-Oncogene Proteins c-akt - Abstract
The phosphoinositide 3-kinase (PI3K/Akt) pathway is activated in acute myelogenous leukemia (AML) and is promising for targeted inhibition. Ninety-two patients with primary AML were analyzed for PI3K/Akt constitutive activation. Fifty percent of the patients presented with constitutive PI3K activation (PI3K +). No difference was observed between PI3K + and PI3K − groups concerning age, sex, white blood cell count, lactate dehydrogenase (LDH) level, bone marrow blast cells, French-American-British (FAB) classification, cytogenetics, RAS or nucleophosmin (NPM) mutations. Slightly more FLT3-ITD was detected in the PI3K − group (P = .048). The complete remission rate was similar between the 2 groups. With a median follow-up of 26 months, we observed for PI3K + and PI3K − patients, respectively, 56% and 33% overall survival (P = .001) and 72% and 41% relapse-free survival (P = .001). Constitutive PI3K/Akt activity is a favorable prognosis factor in AML, even after adjustment for FLT3-ITD, and may confer a particular sensitivity to chemotherapy. A better understanding of the downstream effectors of the PI3K/Akt pathway is needed before targeting in AML.
- Published
- 2007